Genmab
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
- Conditions
- Cutaneous MelanomaRelapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)Metastatic Cutaneous Melanoma (Stage IV)
- Interventions
- First Posted Date
- 2025-05-22
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 90
- Registration Number
- NCT06984328
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 3
- Registration Number
- NCT06771921
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸NEXT Oncology Madrid, Madrid, Spain
🇩🇰Righshospitalet (Copenhagen University Hospital), Copenhagen, Denmark
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 260
- Registration Number
- NCT06685068
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
- Conditions
- PD-L1-positive Metastatic NSCLC
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Genmab
- Target Recruit Count
- 702
- Registration Number
- NCT06635824
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Ocala Oncology Center P.L., Ocala, Florida, United States
🇺🇸Orlando Regional Medical Center, Orlando, Florida, United States
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-26
- Lead Sponsor
- Genmab A/S
- Target Recruit Count
- 171
- Registration Number
- 2024-514822-21-00
- Locations
- 🇦🇹
Ordensklinikum Linz GmbH, Linz, Austria
🇦🇹Medizinische Universitaet Innsbruck, Innsbruck, Austria
🇦🇹Klinik Hietzing, Vienna, Austria
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
- Conditions
- Advanced Malignant Solid TumorMetastatic Malignant Solid Tumor
- Interventions
- Drug: Premedication
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 45
- Registration Number
- NCT06573294
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸Start Madrid Centro Integral Oncologico Clara Campal CIOCC, Madrid, Spain
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Genmab
- Target Recruit Count
- 360
- Registration Number
- NCT06508658
- Locations
- 🇺🇸
Valkyrie Clinical Trials /ID# 269935, Los Angeles, California, United States
🇺🇸Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823, Golden, Colorado, United States
🇺🇸Northwest Cancer Center - Dyer Clinic /ID# 269787, Dyer, Indiana, United States
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
- Conditions
- Malignant Solid Tumor
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 21
- Registration Number
- NCT06391775
- Locations
- 🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States
🇪🇸Hospital Universtari Val D´Hebron, Barcelona, Spain
🇪🇸Start Madrid Ciocc Hm Sanchinarro, Madrid, Spain
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- Conditions
- Follicular Lymphoma (FL)
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Genmab
- Target Recruit Count
- 1095
- Registration Number
- NCT06191744
- Locations
- 🇺🇸
Sansum Clinic Research /ID# 261596, Santa Barbara, California, United States
🇺🇸Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States
🇺🇸Christiana Care Health Service /ID# 261207, Newark, Delaware, United States
PRO1107 in Patients With Advanced Solid Tumors
- Conditions
- Endometrial CancerTriple Negative Breast CancerNon-small Cell Lung CancerUrothelial CarcinomaOvarian CancerGastroEsophageal Cancer
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 280
- Registration Number
- NCT06171789
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States